NovaBay® Pharmaceuticals, Inc. announces that management is scheduled to present a corporate overview at the H.C. Wainwright 20th Annual Global Investment Conference on Thursday, September 6, 2018
A live webcast and replay will be available on the Investors section of the Company’s website at http://novabay.com/investors/events.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, NEUTROPHASE® for wound care market, and CELLERX® for the aesthetic dermatology market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets.
Socialize and Stay informed on NovaBay’s progress:
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay’s Website
View source version on businesswire.com: https://www.businesswire.com/news/home/20180830005065/en/
Contacts
NovaBay Pharmaceuticals, Inc.
For NovaBay Avenova+ purchasing information:
Please call us toll free: 1-800-890-0329 or email sales@avenova.com
www.Avenova.com
or
From the Company:
Jack McGovern, 510-899-8800
Chief Financial Officer
jmcgovern@novabay.com
or
Investors:
LHA Investor Relations
Jody Cain, 310-691-7100
Jcain@lhai.com
Source: NovaBay Pharmaceuticals, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20180830005065/en
